Pharmaceutical company Pfizer recently announced it would no longer fund research into treatments for Parkinson’s and Alzheimer’s diseases.
An estimated 5.5 million Americans suffered from Alzheimer’s last year, and approximately 60,000 Americans are diagnosed with Parkinson’s every year. Those numbers come from the respective advocacy groups.
To talk about the impact of Pfizer’s move away from research into a treatment for these diseases is Ken Kaitin, director of the Center for the Study of Drug Development at Tufts University.
